Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere
- PMID: 38340760
- DOI: 10.1016/S2468-1253(24)00004-9
Haematopoietic stem-cell transplantation for patients with Crohn's disease: primum non nocere
Conflict of interest statement
We declare no competing interests. We acknowledge the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT) for its support in providing updated registry data for this manuscript, as well as all EBMT member centres and their clinicians, data managers, and patients for their valuable contributions to the EBMT registry. The EBMT is in the process of migrating data into a new registry application and only partial data is currently available for 2023.
Comment on
-
Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial.Lancet Gastroenterol Hepatol. 2024 Apr;9(4):333-345. doi: 10.1016/S2468-1253(23)00460-0. Epub 2024 Feb 7. Lancet Gastroenterol Hepatol. 2024. PMID: 38340759 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
